Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EPO

- PMLiVE

Size matters?

Pfizer’s $160bn deal to acquire Allergan will challenge the new company to show that big is better

The future of Pfizer(s)

Current headlines point to a frightening journey

- PMLiVE

Pfizer settles US Protonix lawsuit for $785m

US government deal covers Wyeth’s failure to pay drug rebates

EU flag

Sandoz files for approval of Neulasta biosimilar in Europe

Amgen facing increasing competition in global biosimilar market

- PMLiVE

Lantus sales decline as competition heats up at Sanofi

Brand affected by biosimilars, growth of other new drugs and pricing pressure

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

- PMLiVE

Pfizer to form specialty drugs unit after Allergan takeover

Will merge its consumer portfolio with Allergan's ophthalmology and aesthetics brands

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

- PMLiVE

Soaring sales of Pfizer’s Prevnar lead to calls for price cut

Revenue from the family of pneumonia vaccines rose 43% in the fourth quarter

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux

Research Partnership

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links